DMC approves colorectal cancer cohort expansion
Faron Pharmaceuticals Oy ("Faron" or the "Company") MATINS TRIAL UPDATE Data monitoring committee approves initiation of expansion cohort in colorectal cancer patients Company announcement, 13 January 2020 at 9.00 AM (EET)Inside information TURKU - FINLAND - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, today announces approval from the MATINS trial's data monitoring committee ("DMC") to initiate the study's first expansion cohort, Part II, in patients suffering from late-stage colorectal cancer (